KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice

European Journal of Pharmacology

Volumn 454, Issue 1, 2002, Pages 85-93

  Noji, Tohru ^a   Nan ya, Ken ichiro ^a   Mizutani, Mirai ^a   Katagiri, Chikako ^a   Sano, Jun ichi ^a   Takada, Chie ^a   Nishikawa, Satoshi ^a   Karasawa, Akira ^a   Kusaka, Hideaki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Acute pancreatitis; Adenosine; KF24345; Mortality; TNF (Tumor necrosis factor ); Uptake inhibition

Indexed keywords

3 [1 (6,7 DIETHOXY 2 MORPHOLINOQUINAZOLIN 4 YL)PIPERIDIN 4 YL] 1,6 DIMETHYL 2,4(1H,3H) QUINAZOLINEDIONE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; AMYLASE; CHOLINE; ETHIONINE; KF 24345; LACTATE DEHYDROGENASE; QUINAZOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3 (1 (6,7 DIETHOXY 2 MORPHOLINOQUINAZOLIN 4 YL)PIPERIDIN 4 YL) 1,6 DIMETHYL 2,4 (1H,3H) QUINAZOLINEDIONE; 3-(1-(6,7-DIETHOXY-2-MORPHOLINOQUINAZOLIN-4-YL)PIPERIDIN-4-YL)-1,6-DIMETHYL-2,4-(1H,3H)-QUINAZOLINEDIONE; NEUROTRANSMITTER UPTAKE INHIBITOR; PYRIMIDINONE DERIVATIVE;

ACINAR CELL; ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HYPERAMYLASEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHALITY; MORTALITY; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; ACUTE DISEASE; ANIMAL; BLOOD; DIET; DRUG ANTAGONISM; METABOLISM; ORGAN SIZE; PANCREAS; PANCREATITIS; TIME; VITAMIN DEFICIENCY;

ACUTE DISEASE; ADENOSINE; AMYLASES; ANIMALS; CHOLINE DEFICIENCY; DIET; FEMALE; L-LACTATE DEHYDROGENASE; MICE; NEUROTRANSMITTER UPTAKE INHIBITORS; ORGAN SIZE; PANCREAS; PANCREATITIS; PYRIMIDINONES; QUINAZOLINES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036842959     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02476-7     Document Type: Article

References (43)

1. Banks P.A. Medical management of acute pancreatitis and complications. Go V.L., DiMagno E.P., Gardner J.D., Lebenthal E., Reber H.A., Scheele G.A. The Pancreas: Biology, Pathobiology, and Disease. 1993;593-611 Raven, New York, NY.
2. Bhatia M., Saluja A.K., Hofbauer B., Lee H.S., Frossard J.L., Steer M.L. The effects of neutrophil depletion on a completely noninvasive model of acute pancreatitis-associated lung injury. Int. J. Pancreatol. 24:1998;77-83.
3. Collis M.G., Hourani S.M.O. Adenosine receptor subtypes. Trends Pharmacol. Sci. 14:1993;360-366.
4. Cronstein B.N. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J. Invest. Med. 43:1995;50-57.
5. Cronstein B.N. Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;285-299 Wiley-Liss, New York, NY.
6. Denham W., Yang J., Fink G., Denham D., Carter G., Ward K., Norman J. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis. Gastroenterology. 113:1997;1741-1746.
7. Grady T., Liang P., Ernst S.A., Logsdon C.D. Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis. Gastroenterology. 113:1997;1966-1975.
8. Johnson S.M., Patel S., Bruckner F.E., Collins D.A. 5′-Nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology. 38:1999;391-396.
9. 2A receptor antagonist. Eur. J. Pharmacol. 301:1996;107-113.
10. Konturek S.J., Dembinski A., Konturek P.J., Warzecha Z., Jaworek J., Gustaw P., Tomaszewska R., Stachura J. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut. 33:1992;1268-1274.
11. Kowaluk E.A., Bhagwat S.S., Jarvis M.F. Adenosine kinase inhibitors. Curr. Pharm. Des. 4:1998;403-416.
12. Leach S.D., Modlin I.M., Scheele G.A., Gorelick F.S. Intracellular activation of digestive zymogens in rat pancreatic acini. Stimulation by high doses of cholecystokinin. J. Clin. Invest. 87:1991;362-366.
13. Liu G.S., Downey J.M., Cohen M.V. Adenosine, ischemia, and preconditioning. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;153-172 Wiley-Liss, New York, NY.
14. Lüthen R.E., Niederau C., Grendell J.H. Intrapancreatic zymogen activation and levels of ATP and glutathione during caerulein pancreatitis in rats. Am. J. Physiol. 268:1995;G592-G604.
15. 1-receptor antagonist, via pertussis toxin insensitive mechanism. J. Pharmacol. Exp. Ther. 266:1993;200-206.
16. Moser G.H., Schrader J., Deussen A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256:1989;C799-C806.
17. Murray T.F., Sylvester D., Schultz C.S., Szot P. Purinergic modulation of the seizure threshold for pentylenetetrazol in the rat. Neuropharmacology. 24:1985;761-766.
18. Niederau C., Liddle R.A., Ferrell L.D., Grendell J.H. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. J. Clin. Invest. 78:1986;1056-1063.
19. Niederau C., Ude K., Niederau M., Lüthen R., Strohmeyer G., Ferrell L.D., Grendell J.H. Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis. Pancreas. 6:1991;282-290.
20. Niederau C., Niederau M., Borchard F., Ude K., Lüthen R., Strohmeyer G., Ferrell L.D., Grendell J.H. Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis. Pancreas. 7:1992;486-496.
21. Noji T., Takayama M., Mizutani M., Okamura Y., Takai H., Karasawa A., Kusaka H. KF24345, an adenosine uptake inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor-α production and leukopenia via endogenous adenosine in mice. J. Pharmacol. Exp. Ther. 300:2002;200-205.
22. Noji, T., Nan-ya, K., Katagiri, C., Mizutani, M., Sano, J., Nishikawa, S., Karasawa, A., Kusaka, H. Adenosine uptake inhibition ameliorates cerulein-induced acute pancreatitis in mice. Pancreas, in press.
23. 1 receptors. Br. J. Pharmacol. 117:1996;1645-1652.
24. Norman J.G., Fink G.W., Messina J., Carter G., Franz M.G. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surgery. 120:1996;515-521.
25. Ogawa M. Acute pancreatitis and cytokines: "second attack" by septic complication leads to organ failure. Pancreas. 16:1998;312-315.
26. Olah M.E., Stiles G.L. The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther. 85:2000;55-75.
27. 2a selective adenosine receptor antagonist. Br. J. Pharmacol. 115:1995;1096-1102.
28. 2a adenosine receptor antagonist, after enteric administration in rat, cat and dog. J. Pharm. Pharmacol. 48:1996;601-606.
29. Quéré I., Hillaire-Buys D., Brunschwig C., Chapal J., Janbon C., Blayac J.P., Petit P., Loubatières-Mariani M.M. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats. Br. J. Pharmacol. 122:1997;351-357.
30. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
31. Rosengren S., Firestein G.S. Purinergic modulation of septic shock and systemic inflammation response syndrome. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;301-313 Wiley-Liss, New York, NY.
32. 1-receptor pathway induces edema formation in the pancreas of rats. Gastroenterology. 119:2000;829-836.
33. 2a receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis. Pancreas. 24:2002;75-82.
34. Sawynok J., Sweeney M.I., White T.D. Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br. J. Pharmacol. 88:1986;923-930.
35. 1-adenosine receptors. J. Med. Chem. 35:1992;924-930.
36. Silverman M., Ilardi C., Bank S., Kranz V., Lendvai S. Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice. Gastroenterology. 96:1989;186-192.
37. Steer M.L. Etiology and pathophysiology of acute pancreatitis. Go V.L., DiMagno E.P., Gardner J.D., Lebenthal E., Reber H.A., Scheele G.A. The Pancreas: Biology, Pathobiology, and Disease. 1993;581-592 Raven, New York, NY.
38. Steer M.L. The early intraacinar cell events which occur during acute pancreatitis. Pancreas. 17:1998;31-37.
39. Steinle A.U., Weidenbach H., Wagner M., Adler G., Schmid R.M. NF-κB/Rel activation in cerulein pancreatitis. Gastroenterology. 116:1999;420-430.
40. von Lubitz D.K., Dambrosia J.M., Kempski O., Redmond D.J. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke. 19:1988;1133-1139.
41. Williams M. Progress towards purinoceptor based therapeutics. Curr. Opin. Investig. Drugs. 2:1996;1105-1117.
42. Yamagishi F., Homma N., Haruta K., Iwatsuki K., Chiba S. Adenosine potentiates secretin-stimulated pancreatic exocrine secretion in the dog. Eur. J. Pharmacol. 118:1985;203-209.
43. Yeung P.K.F., Mosher S.J., Macrae D.A., Klassen G.A. Effect of diltiazem and its metabolites on the uptake of adenosine in blood: an in vitro investigation. J. Pharm. Pharmacol. 43:1991;685-689.